[High-dose vitamin therapy as prophylaxis against porphyria cutanea uremica].
50 Patients with chronic renal failure undergoing hemodialysis with or without porphyria cutanea tarda (PCT)-like skin changes were investigated. The total porphyrin amount in erythrocytes, plasma and dialysate and the distribution of porphyrin metabolites in plasma and dialysate were measured. In plasma, the group of patients with skin changes (referred as PCU = porphyria cutanea uremica) showed significantly increased uroporphyrin levels as compared to the non-symptomatic group. In addition, significant differences concerning the ratio uro-/coproporphyrin in plasma were shown: non-symptomatic patients with 0.87, as opposed to the PCU group with 3.7. Considerable differences between the level of vitamin ingestion were identified between the groups. Patients with PCU took distinctly less vitamins C, E and B than patients without symptoms.
Wimmershoff
F
F
Hautklinik der Medizinischen Fakultät des Universitätsklinikums Düsseldorf.
Gardlo
K
K
Bolsen
K
K
Ruzicka
T
T
Fritsch
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001205:Ascorbic Acid / Q000008:administration & dosage; D003306:Coproporphyrins / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control*; D012016:Reference Values; D006435:Renal Dialysis; D012307:Risk Factors; D014511:Uremia / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control*; D014578:Uroporphyrins / Q000097:blood; D014803:Vitamin B Complex / Q000008:administration & dosage; D014810:Vitamin E / Q000008:administration & dosage; D014815:Vitamins / Q000008:administration & dosage*
D003306:Coproporphyrins; D014578:Uroporphyrins; D014815:Vitamins; D014803:Vitamin B Complex; D014810:Vitamin E; D001205:Ascorbic Acid